key: cord-1028926-dv3v86di authors: Frioui, Refka; Chamli, Amal; Zaouak, Anissa; Hlel, Imen; Khanchel, Fatma; Fenniche, Samy; Hammami, Houda title: A case of new‐onset acute generalized pustular psoriasis following Pfizer‐BioNTech COVID‐19 vaccine date: 2022-04-06 journal: Dermatol Ther DOI: 10.1111/dth.15444 sha: 72aa4665cfd40babfbba1b41f7bb085f8fb38247 doc_id: 1028926 cord_uid: dv3v86di nan Our patient presented an acute onset of AGPP 4 days after receiving the first dose of the mRNA-CV. The Known causes of AGPP were excluded. According to the Naranjo criteria, the likelihood of the vaccine as the incriminating agent was highly significant and the score was six "probable." 1 Clinical case discussion concluded that while idiopathic AGPP could not be excluded, the onset of symptoms was consistent with an acute precipitating event around the time the first vaccine dose was administered. In summary, we reported here the second case of AGPP following mRNA-CV. Although vaccines against COVID-19 could aggravate already existing psoriasis, trigger psoriasis de novo, or, as reported herein, modify the phenotype of the disease, psoriatic patients should receive the vaccine since its benefits overweigh its side effects. 9 None. The authors declare no potential conflict of interest. The examination of the patient was conducted according to the principles of the Declaration of Helsinki. The authors certify that they have obtained all appropriate patient consent forms, in which the patient gave his consent for images and other clinical information to be included in the journal. The patient understands that his name and initial will not be published and due effort will be made to conceal his identity, but that anonymity cannot be guaranteed. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. A method for estimating the probability of adverse drug reactions Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine Generalized pustular psoriasis following COVID-19 Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells Vaccines against SARS-CoV-2 in psoriasis patients on immunosuppressive therapy: implications of vaccination nationwide campaign on clinical practice in Italy F I G U R E 2 Psoriasiform hyperplasia of the epidermis containing macropustule (HEx100)